Product Description
alpha-2c adrenoceptor antagonist (Sourced from: https://www.orion.fi/en/Orion-group/media/stock-exchange-releases/2014/orion-group-financial-statement-release-for-2013/)
Mechanisms of Action: ADRA2C Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Orion Pharma
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Healthy Volunteers
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01839019 |
NCT01839019 | P1 |
Completed |
Healthy Volunteers |
2013-06-01 |
2019-03-19 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|